🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The impact and role of a clinical pharmacist in a community oncology setting is not well-described in the literature. In this study, researchers evaluated the impact of remote clinical reviews by oncology pharmacists in community oncology practices. bit.ly/3xT2mbI

The COVID-19 pandemic caused an unprecedented challenge with supply and demand of staff disruption in the healthcare system. In this study, researchers evaluated the impact of oncology pharmacy residents’ learning experiences during the pandemic. bit.ly/3MtwIW5

Researchers conducted a retrospective study to determine the total financial support obtained by University of Rochester Specialty Pharmacy to help relieve patients from financial toxicity associated with oral oncolytic medications. bit.ly/3OuHz45

Researchers conducted a survey to find out the perceptions of PGY2 oncology pharmacy residents and residency program directors about financial toxicity and the self-perceptions of their ability and experience in managing financial toxicity for patients. bit.ly/3rQZ2K5

A pilot study aimed to characterize an oral chemotherapy monitoring program for patients with leukemia, and to quantify and describe the types of patient-centered activities performed. bit.ly/3Li7Y2O

A study aimed to determine if an online continuing education (CE) curriculum consisting of online, video-recorded discussions could improve pharmacists’ ability in managing patients with solid tumors who are receiving immune checkpoint inhibitors. bit.ly/3Mrxi6T

Researchers evaluated newly diagnosed patients with acute myeloid leukemia (AML) to describe the duration of neutropenia and thrombocytopenia in patients receiving Clad/LDAC and venetoclax with concomitant azoles. bit.ly/3LjvHja

Researchers discussed cases of 3 patients with acute promyelocytic leukemia and prolonged QTc interval that resulted from arsenic trioxide therapy, who benefited from a beta-blocker used to shorten the QTc interval. bit.ly/3wwkpSz

A research study aimed to determine if the sequencing of oxaliplatin and irinotecan has an impact on the incidence of adverse reactions, including dysarthria, dysphagia, numbness, and gastrointestinal discomfort. bit.ly/3EJXLtH

Researchers evaluated the reliability of the SMARTeZ elastomeric pump to deliver 5-FU, by measuring the percentage of pumps that deliver >90% of expected 5-FU dose at the end of 46 hours of infusion. bit.ly/3ve25yh

A retrospective study compared the time to treatment initiation (TTI) and outcomes in patients with nonmetastatic breast cancer before and during the COVID-19 pandemic. bit.ly/3MoWOJK

The University of Texas MD Anderson Cancer Center implemented a best practice advisory (BPA) within the electronic health record (EHR) system to alert prescribers of any abnormal HBV screening results when placing chemotherapy orders. bit.ly/3LlanJr

A study evaluated the rates of CMV infection at week 24 before and after the implementation of CMV prophylaxis with letermovir in high-risk HSCT recipients who are CMV-seropositive or CMV-seronegative with a CMV-seropositive stem-cell donor. bit.ly/3wj1hZx

A study evaluated the incidence of grade 3 or 4 adverse events from chemotherapy in patients with breast cancer who are concomitantly receiving antiretroviral therapy for HIV, as well as the effects of chemotherapy on the management of HIV infection. bit.ly/38xawMv

Researchers reviewed and compared the pharmacology, efficacy, safety, and drug interactions of second-generation antiandrogens based on the published literature. bit.ly/3lh1J48

A clinical trial compared the benefits of the PD-1 inhibitor pembrolizumab plus chemotherapy versus placebo plus chemotherapy in treatment-naïve patients with early-stage, triple-negative breast cancer (TNBC). bit.ly/3NfMbcO

A clinical trial compared axicabtagene ciloleucel with standard of care in the second-line setting for patients with early relapsed or refractory large B-cell lymphoma. bit.ly/3sAsQLl

Esophageal cancer is a leading cause of cancer-related mortality worldwide. A study investigated effects of first-line combination immunotherapy with the PD-1 inhibitor nivolumab plus the CTLA-4 inhibitor ipilimumab. bit.ly/3MjsmkB

A clinical trial investigated effects of treatment with the androgen receptor inhibitor darolutamide, in combination with androgen-deprivation therapy (ADT) and docetaxel, in patients with metastatic hormone-sensitive prostate cancer (HSPC). bit.ly/3Portcu

A clinical trial investigated effects of neoadjuvant therapy with enfortumab vedotin in patients with muscle-invasive bladder cancer who were ineligible for cisplatin therapy. bit.ly/38q5DoE